pittplusme.org/study/2121
Metabolic Interventions to Resolve NASH with Fibrosis (MIRNA)
STUDY BASICS
Are you 18-75 and diagnosed with a type of liver disease called non-alcoholic steatohepatitis (NASH)? You may be able to participate in a study to test two investigational drugs (study drugs) being developed as potential options to treat patients with NASH with liver fibrosis. This study involves at least 16 visits over up to 68 months. Compensation is provided.
IRB: 20200277
- A PHASE 2, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, DOSERANGING, DOSE-FINDING, PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF-06865571 (DGAT2I) ALONE AND WHEN COADMINISTERED WITH PF-05221304 (ACCI) IN ADULT PARTICIPANTS WITH BIOPSY-CONFIRMED NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS STAGE 2 OR 3
AGE:
18-75
DURATION:
Up to 68 weeks
VISITS:
At least 16
LOCATION:
UPMC Center for Liver Diseases - Oakland
COMPENSATION:
Up to $1,020
SHARE STUDY
